Overall, BRAF mutations in NSCLC show an intermediate frequency between EGFR mutations and ROS1 rearrangements, similar to ALK rearrangement [25], and deserve special attention for the possible use of targeted therapy. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.